Robust Glycemic Outcomes after MiniMed Advanced Hybrid Closed-Loop (AHCL) System Use in the Pivotal Trial Regardless of Previous Therapy

Background: The Medtronic MiniMed™ AHCL system that autocorrects to 120mg/dL every five minutes and has an automated basal target of 100mg/dL or 120mg/dL has demonstrated improved A1C and time in range1,2 or improved time in closed-loop control,3 compared to open-loop run-in or control. Glycemic outcomes of study participants who used a different baseline therapy (HCL, SAP or CSII) during the MiniMed™ AHCL pivotal trial were analyzed.Methods: Across 16 sites, participants (N=157, 14-75 years) with T1D underwent a baseline run-in period (~2 weeks) of HCL, SAP or CSII followed by a 90-day study phase with AHCL automated basal and auto-correction. An exploratory analysis compared the mean sensor glucose and percentage of time spent across glucose ranges during the baseline run-in and AHCL-study phase for each cohort.Results: Glycemic outcomes for the overall group and each cohort are shown in the table. Significant changes were observed from run-in to study period for the overall group. The glycemic outcomes that were achieved were similar regardless of the baseline therapy.Conclusion: These MiniMed™ AHCL pivotal trial data demonstrate that the system achieves robust glycemic improvement regardless of baseline therapy.View largeDownload slideView largeDownload slide DisclosureJ. Shin: Employee; Self; Medtronic. X. Chen: None. M. Liu: None. S. Huang: None. T. L. Cordero: Employee; Self; Medtronic. A. S. Rhinehart: Employee; Self; Medtronic, Stock/Shareholder; Self; AstraZeneca, Lexicon Pharmaceuticals, Inc., Medtronic. R. Vigersky: Employee; Self; Medtronic.FundingMedtronic